

11 Dec 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: US prospects for Sarepta's DMD gene therapy; looking at price increases in the US; Eisai plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-*Novo Nordisk* CEO Mads Øvlisen shares his career and life lessons.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 December 2022, including: US prospects for [*Sarepta Therapeutics, Inc.*](#)'s DMD gene therapy; looking at price increases in the US; [*Eisai Co., Ltd.*](#) plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-[*Novo Nordisk A/S*](#) CEO Mads Øvlisen shares his career and life lessons.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[A Duchenne Breakthrough Awaits In 2023 - But Risks Remain For Sarepta And US FDA](#)" - *Scrip*, 6 Dec, 2022.)

(Also see "[Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List](#)" - *Scrip*, 6 Dec, 2022.)

(Also see "[Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab](#)" - *Scrip*, 2 Dec, 2022.)

(Also see "[*China Winds Down 'COVID Zero' But Vaccine Fatigue, Other Worries Linger*](#)" - Scrip, 6 Dec, 2022.)

(Also see "[*Lessons From Novo Nordisk's Mads Øvlisen, The Father Of CSR*](#)" - Scrip, 6 Dec, 2022.)

[Click here to explore this interactive content online](#) ✎